Meningococcal Vaccines Market in 8MM Reviewed & Projected by GlobalData in Topical Report Published at MarketPublishers.com

02 Mar 2016 • by Natalie Aster

LONDON – Vaccines that are available today protect against all serotypes A, B, C, W-135, and Y and use the polysaccharide as antigens, however, no single vaccine is capable of protecting against all serogroups synchronously. The growth in the meningococcal vaccines market is expected to be driven by the recent advent of serotype B vaccines that address a key unmet need in today’s therapeutic landscape, and also increased coverage rates of currently available routine vaccination programmes.

The meningococcal vaccine market in the USA, 5EU, Australia and Brazil are expected to grow from close to USD 1.1 billion in 2012 to USD 1.5 billion by 2022, at 3% CAGR. This growth across the 8 key geographies is expected to be driven by the 5EU owing to the usage of serogroup B vaccines in the routine infant immunisation schedule. Furthermore, in the USA, college students, for example, are receiving the newly approved vaccines against serogroup B, which also contributes to the growth of the market; whilst the commercial meningococcal vaccine market in Brazil will post a negative CAGR of 16.3%.

The major opportunities will likely lie in enhancing vaccine efficacy, particularly in the emerging vaccines against serogroup B whilst addressing the cost-effectiveness concerns expressed by different government agencies.

Topical market research report “PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData examines the meningococcal vaccine marketplace in the 8 major markets discussed. It gives an overview of disease, covering epidemiology, aetiology, regional serogroup distribution, etc.; provides top-level market revenues from 2012 and up to 2022, with recent acquisitions, approvals and recommendations included. The report presents a detailed competitive assessment covering key products, market characterisation, key unmet needs, R&D strategies, and pipeline analysis for the market covering clinical trial mapping and promising vaccines in development. The research study looks into the present-day and future market competition in the world’s meningococcal vaccine market. It also offers an insightful overview of the most essential industry drivers, hindrances and challenges.

Report Details:

PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2022
Published: December, 2015
Pages: 290 
Price: US$ 10,995.00 

More studies by the publisher can be found at GlobalData page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 
MarketPublishers.com